Active	Status	Sponsor type	Region	Phase	Filter
10 Active 0 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ross, Jeffrey
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease	Active, not recruiting	3	1083	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	05/25	05/25
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease	Recruiting	3	600	Japan, US	Remternetug (IV), LY3372993, Remternetug (SC), Placebo	Eli Lilly and Company	Alzheimer's Disease	10/25	10/26
NCT05026866: A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)	Recruiting	3	2600	Japan, US	Donanemab, LY3002813, Placebo	Eli Lilly and Company	Alzheimer Disease	11/27	11/27
NCT04733989: A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)	Completed	N/A	1002	US	Biomarker Data Collection	GAP Innovations, PBC	Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment	11/22	11/22
NCT05046158: Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care	Recruiting	N/A	200	US	Transforming Powder Dressing, Altrazeal, Standard of care topical wound agents and dressings	ULURU Inc., Naval Medical Research Center, Military Technology Enterprise Consortium (US)	Diabetic Foot Ulcer	12/23	12/23
Asada, Takashi
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease	Recruiting	3	600	Japan, US	Remternetug (IV), LY3372993, Remternetug (SC), Placebo	Eli Lilly and Company	Alzheimer's Disease	10/25	10/26
GOETSCH, NICHOLAS
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease	Recruiting	3	600	Japan, US	Remternetug (IV), LY3372993, Remternetug (SC), Placebo	Eli Lilly and Company	Alzheimer's Disease	10/25	10/26
NCT05026866: A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)	Recruiting	3	2600	Japan, US	Donanemab, LY3002813, Placebo	Eli Lilly and Company	Alzheimer Disease	11/27	11/27
Isozaki, Mitsuhiro
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease	Recruiting	3	600	Japan, US	Remternetug (IV), LY3372993, Remternetug (SC), Placebo	Eli Lilly and Company	Alzheimer's Disease	10/25	10/26
CO, Sound Wave Innovation
NCT05983575: A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease	Recruiting	3	220	Japan	LIPUS-Brain, Placebo	Sound Wave Innovation CO., LTD.	Alzheimer Disease, Early Onset	01/26	07/26